Synthelabo's devices sales growth estimated at 7%:
This article was originally published in Clinica
Sales at Synthelabo's pacemakers and catheters divisions are estimated to grow 7% over the next five years, concludes a report by US analysts Morgan Stanley. They expect "no dramatic developments" in Ela Medical's pacemaker and ECG business over the next few years. Porges' catheter and urology products division reported sales of Fr 173 million ($36 million) in 1994, while Ela Medical posted Fr 489 million revenues for the year. Medical devices represented around 8% of the company's revenues in 1994.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.